A diagnosis of diabetes mellitus (DM) exposes an individual to multiple metabolic abnormalities, degraded neural function, loss of eyesight, and signifi cant risk to essential organs like the kidneys, heart, and brain.
C A S E R E P O R T
A diagnosis of diabetes mellitus (DM) exposes an individual to multiple metabolic abnormalities, degraded neural function, loss of eyesight, and signifi cant risk to essential organs like the kidneys, heart, and brain. 7 For these reasons, worldwide space programs have traditionally disqualifi ed individuals with DM from selection as astronauts despite multiple treatment options available for management of this condition, resulting in a paucity of actual operational data concerning diabetics' ability to tolerate the spacefl ight environment.
One eff ective treatment for the sequelae of diabetes is the subcutaneous injection of insulin. 7 Th is can be accomplished with hypodermic needles or with an indwelling pump using a refi llable reservoir to deliver insulin through a semipermanently implanted needle. However, if too much insulin is delivered, or if insulin is delivered at the wrong time, the individual may develop sudden and profound hypoglycemia. Th is bears the risk of causing major lapses in judgment, decreased executive function, dizziness, fatigue, tremulousness, seizures, or even coma and death, again causing concern over diabetic tolerance and the eff ectiveness of medication treatment and delivery options within high-performance environments. 5 , 7 If an individual using an insulin pump is exposed to the high acceleration forces (G forces) involved in the launch and re-entry profi les of spacefl ight, these stressors could disrupt the pump ' s function and cause anything from a simple dislodgment of the needle to an inappropriately timed or dosed bolus of insulin, potentially rendering that individual incapacitated from hypo/ hyperglycemia. 3 Th ere is limited information regarding the tolerance of commercial spacefl ight participants, who are expected to have a much wider range of physical and medical conditions than the well-trained career astronaut, to the acceleration profi les of a commercial spacefl ight. 3 Currently, much speculation exists regarding whether or not commercial spacefl ight poses increased risk to individuals with medical disease or other physiological limitations.
1 , 2 Interestingly, the advent of commercial spacefl ight does change the risk profi le of spacefl ight missions, as commercial spacefl ight participants (SFPs) are, for now, simply passengers with no mission critical tasks to perform. 6 Th us, if an SFP is incapacitated from a medical problem, the SFP poses a far lower risk to the remaining passengers, pilot, and vehicle than the traditional mission-critical astronaut. 1 , 2 , 4 Th is change in risk profi le permits a tolerance for many of the chronic medical problems associated with DM, but does not change the personal risks associated with rapid, dramatic shift s in blood glucose levels. If the individual uses an implantable pump these risks may be even higher. A search of the literature did not reveal any studies addressing the tolerance of high-acceleration fl ight profi les in diabetics. Further, no studies were found regarding exposure of individuals with implantable insulin pumps to the acceleration forces expected during spacefl ight. Th is case report details the experience of two insulin-dependent Type I diabetics with implanted insulin pumps exposed to sustained acceleration forces in a centrifuge as a part of a larger study regarding layperson tolerance to acceleration.
3

CASE REPORT
Two subjects with Type I DM, both with indwelling Humalog insulin pumps, volunteered to participate in centrifuge trials. Subject 1 was a 23-yr-old man diagnosed with DM at age 16, averaging 50 u of Humalog daily via insulin pump. Subject 2 was a 27-yr-old man diagnosed with DM at age 11, averaging 60 u of Humalog daily via insulin pump. Past medical history for both subjects was otherwise unremarkable.
Both subjects underwent seven centrifuge runs over 2 d at the National Aerospace Training and Research (NASTAR) Center centrifuge (Environmental Tectonics Corp., Southampton, PA) as a part of a larger trial.
3 Day 1 consisted of two +G z runs (peak 5 +3.5 G z , run 2) and two +G x runs (peak 5 +6.0 G x , run 4). Day 2 consisted of three runs approximating suborbital spacefl ight profi les (combined +G x /+G z ). 3 Participants experienced training runs in a high-performance centrifuge with both rapid onset acceleration and sustained acceleration capabilities. Th e passenger gondola contains a passenger seat and a high-fi delity multimedia system designed to provide audiovisual simulation to enhance the realism of the spaceflight experience. Audio communication with the participants was provided through speakers in the gondola and a live microphone. Real-time video imaging of the test subject ' s face and torso was projected to the test operator, test director, and medical monitors at all times. A three-lead electrocardiogram, automatic blood pressure cuff , and fi nger pulse oximetry were used to monitor the participants. While subjects were not required to monitor their blood glucose, both subjects voluntarily monitored their own glucose levels using a fi nger stickbased point-of-care blood glucose analyzer following the centrifuge experiences.
At the testing facility, resting blood pressure and heart rate were recorded prior to initiating the centrifuge runs. Th e participants were taught the basics of anti-G straining and the " hook " maneuver. Th ey were advised to strain as needed by pressing on adjustable rigid pedals located on the fl oor of the gondola, but to use the hook maneuver only in the event of greyout symptoms. Audiovisual simulation consisted of a projected monitor screen with cockpit-simulated views of Earth and space images imitating real-time views throughout the fl ight profi le, with matching fl ight-related sounds such as rocket engines fi ring. Th ese simulated audiovisual profi les were designed to create an experience for the participants as close to an actual suborbital fl ight as possible. 3 Neither subject experienced adverse clinical responses to the centrifuge exposure. Both individuals periodically checked their own blood glucose levels and noted blood glucose levels maintained between 110 -206 mg • dl 2 1 . Detailed information and timing of glucose checks were not recorded and are not available for disclosure. Neither subject reported any subjective symptoms or had any abnormal exam fi ndings pre, post, or during their spin. Physiologically, their experience was similar to the average response of all 86 trial participants (see Table I ) and did not deviate signifi cantly from the experience of normal healthy test subjects for their age group. 3 Both subjects complained of mild disequilibrium upon initial ambulation aft er fi nishing each of the centrifuge runs which resolved within 3-5 steps outside of the gondola. Th is was a common complaint seen in 28 -48% of subjects per run in the larger study. 3 Neither subject experienced nausea. Subject 1 experienced mild greyout, described as " a little tunnel vision " during the launch and reentry phases of the fi nal two combined profi les (runs 6 and 7) on the second day (peak 5 +3.5 G z / +4.0 G x during both run 6 and 7 launch phases; run 6 reentry peak 5 +6.0 G x ; run 7 reentry peak 5 +4.0 G z /4.5 G x ). Th e subject reported resolution of all symptoms with anti-G straining. Subject 2 denied greyout symptoms for all runs. Visual examination of the insulin pump insertion site demonstrated no dermatologic insult or breakdown following any of the centrifuge runs. Further, there was no visual abnormality of either pump following any acceleration exposure; both pumps continued to work normally throughout the experience and neither participant complained of any operational abnormality of their pump at the time of follow-up approximately 1 mo aft er completion of the centrifuge experience.
DISCUSSION
While it is diffi cult to extrapolate from case reports alone, these cases suggest that the acceleration forces anticipated for commercial suborbital spacefl ight are tolerable for both insulindependent diabetics in otherwise good health and for indwelling medical devices such as insulin pumps. Th e data gathered from these two individuals suggest that there may be little risk to blood glucose levels and the function of exogenous insulin pumps simply from exposure to sustained acceleration forces.
As there is minimal prior literature regarding the performance of individuals with diabetes exposed to the acceleration forces anticipated for commercial spacefl ight, these reports are some of the fi rst indicators that SFPs with diabetes could tolerate suborbital fl ight with little diffi culty. Th ere are several limitations to drawing conclusions from these cases alone. First, the predominant form of DM in the developed world is an acquired insulin resistance (Type II DM) rather than the autoimmune form of the disease. 7 Type II diabetics oft en have many other comorbidities and have a diff erent underlying pathology compared to those with Type I DM. 5 While blood glucose levels and response to insulin did not appear to change to dangerous levels as a function of sustained acceleration, a Type II diabetic wishing to be a commercial SFP would likely need further screening and more careful consideration on a case-by-case basis. Additionally, the use of a centrifuge as an analogue for suborbital spacefl ight is useful to study the eff ects of hypergravity, but cannot simulate microgravity, controlled atmospheres, and other details of an actual spacefl ight, all of which may have their own unique eff ects on insulin pumps and blood glucose levels. Understanding those eff ects will require further investigation. Finally, this report highlights two cases of otherwise healthy and physically fi t individuals with Type I DM. Detailed information regarding infusion rates of the insulin pumps and exact pre/postspin changes in blood glucose were not recorded by either participant and are therefore unavailable. Increasing the sample size of diabetics, particularly those with common comorbidities, who have been subjected to such acceleration exposures will lend greater insight into the eff ects of hypergravity on this disease and the devices used for disease control, as would detailed and controlled data collection regarding blood glucose levels and insulin infusion rates.
Despite these limitations, these cases suggest that the acceleration forces anticipated for commercial suborbital spacefl ight may pose little risk for insulin-dependent diabetics in otherwise good health and may have no apparent eff ect on indwelling medical devices such as insulin pumps. Th is report is the fi rst indication that SFPs with indwelling insulin pumps to control DM might tolerate suborbital spacefl ight with little diffi culty.
